Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS.
Company codeACOG
Company nameAlpha Cognition Inc
IPO dateJun 09, 2021
Founded at2017
CEOMr. Michael Mcfadden
Number of employees52
Security typeOrdinary Share
Fiscal year-endJun 09
Addressc/o 1200 - 750 West Pender Street
CityVANCOUVER
Stock exchangeNASDAQ Capital Market Consolidated
CountryCanada
Postal codeV6C 2T8
Phone16045649244
Websitehttps://www.alphacognition.com/
Company codeACOG
IPO dateJun 09, 2021
Founded at2017
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data